CN103405430A - Applications of corynoxine - Google Patents

Applications of corynoxine Download PDF

Info

Publication number
CN103405430A
CN103405430A CN2013103949131A CN201310394913A CN103405430A CN 103405430 A CN103405430 A CN 103405430A CN 2013103949131 A CN2013103949131 A CN 2013103949131A CN 201310394913 A CN201310394913 A CN 201310394913A CN 103405430 A CN103405430 A CN 103405430A
Authority
CN
China
Prior art keywords
corynoxine
blood pressure
hypertension
hypertensive
applications
Prior art date
Application number
CN2013103949131A
Other languages
Chinese (zh)
Inventor
不公告发明人
Original Assignee
苏州天南星生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州天南星生物科技有限公司 filed Critical 苏州天南星生物科技有限公司
Priority to CN2013103949131A priority Critical patent/CN103405430A/en
Publication of CN103405430A publication Critical patent/CN103405430A/en

Links

Abstract

The invention belongs to the technical field of medicines, and relates to applications of Chinese traditional herb monomer chemical corynoxine for resisting hypertension, and a corynoxine-containing composition used for preventing and treating hypertension.

Description

The purposes of Ke Nuoxin

Technical field

The invention belongs to medical technical field, relate to the purposes of Ke Nuoxin.

Background technology

Hypertension is modal chronic disease, is also the topmost risk factor of cardiovascular and cerebrovascular disease, and apoplexy, myocardial infarction, heart failure and chronic kidney disease are its major complications.Both domestic and external facts have proved, hypertension are the diseases that can prevent and control, reduce hyperpietic's blood pressure level, can obviously reduce apoplexy and the events of heart attack, significantly improve patient's life quality, effectively reduce the disease burden.Hypertensive hazardness and patient's blood pressure level mutually outside the Pass, also depend on the situation of the other diseases of simultaneous other cardiovascular risk factors, target organ damage and merging.Therefore in hypertensive definition and classification, by hypertensive diagnostic criteria fix on systolic pressure >=140mmHg and (or) diastolic pressure >=90mmHg, according to blood pressure level, be divided into normally, outside normal high value blood pressure and 1,2,3 grade of hypertension, also according to the other diseases of risk factor, target organ damage and merging simultaneously, carry out risk stratification simultaneously.

Prevalence of Hypertension raises with age growth; Women's prevalence before climacteric, a little less than the male, but raises rapidly after climacteric, even higher than the male; High latitude cold district prevalence is higher than the warm area of low latitudes, and high altitude localities is higher than low altitude area; Relevant with dietary habit, salt and saturated fat are taken in higher, and mean blood pressure level and prevalence are also higher.Population of China hypertension is popular two relatively outstanding features: from south to the north, Prevalence of Hypertension is and increases progressively trend; Between different nationalities, Prevalence of Hypertension also has some differences, the national prevalence of living in the north or highlands is higher, the national prevalence of living in south or non-highlands is lower, this species diversity may be relevant with geographical environment, life style etc., not yet finds between various nationalities to have obvious genetic background difference.

Treating hypertensive main purpose is to reduce to greatest extent cardiovascular and cerebrovascular vessel morbidity and dead total danger, therefore require the doctor in the hypertensive while for the treatment of, intervene the clinical disease that all reversibility cardiovascular risk factors of patient, target organ damage and merging exist.For general hyperpietic's blood pressure lowering target, be below 140/90mmHg, for high-risk patients such as complication with diabetes or nephropathy, blood pressure should be taken the circumstances into consideration to be down to more low-level in the tolerant situation of patient.

Common depressor has: the Chinese medicine for lowering high blood pressure medicines such as calcium antagonists, RAS depressant, receptor,β blocking agent, diuretic antihypertensive medicine, Niuhuang Jiangya sheet.

Summary of the invention

The object of the present invention is to provide the antihypertensive purposes of Ke Nuoxin (CAS:6877-32-3).

Further, be used to preventing and treating the compositions of the hypertensive Ke Nuoxin of containing.

Ke Nuoxin can effectively reduce blood pressure, and controls preferably the systolic pressure of spontaneous hypertensive rat (SHR).

The specific embodiment

Embodiment 1. Ke Nuoxin hypotensive activities

10~13 week spontaneous hypertensive rats in age (SHR) are pressed to the blood pressure grouping, and concrete dosage is in Table 1, and oral administration is the arteria caudalis pressure measurement after 7 days.

Statistical analysis: measurement data mean+SD Mean t check between relatively employing group of data between two groups.Take P<0.05 is the significance standard.

Result: Ke Nuoxin can effectively reduce the SHR rat blood pressure, and relatively there were significant differences (P<0.05) with model control group, in Table 1.

The impact of table 1. Ke Nuoxin successive administration on the SHR rat blood pressure

With model control group, compare P<0.05.

Claims (2)

1. the purposes of Ke Nuoxin, is characterized in that: the purposes of Ke Nuoxin antihypertensive function.
2. the purposes of Ke Nuoxin according to claim 1, is characterized in that: be used to preventing and treating the compositions of the hypertensive Ke Nuoxin of containing.
CN2013103949131A 2013-09-03 2013-09-03 Applications of corynoxine CN103405430A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2013103949131A CN103405430A (en) 2013-09-03 2013-09-03 Applications of corynoxine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013103949131A CN103405430A (en) 2013-09-03 2013-09-03 Applications of corynoxine

Publications (1)

Publication Number Publication Date
CN103405430A true CN103405430A (en) 2013-11-27

Family

ID=49598505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013103949131A CN103405430A (en) 2013-09-03 2013-09-03 Applications of corynoxine

Country Status (1)

Country Link
CN (1) CN103405430A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101342259A (en) * 2008-06-18 2009-01-14 沈阳药科大学 Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof
CN101862304A (en) * 2010-07-23 2010-10-20 贵州百花医药股份有限公司 Uncaria sustained-release tablet and preparation method thereof
CN102311435A (en) * 2011-07-05 2012-01-11 南京泽朗农业发展有限公司 Preparation method for high purity rhynchophylline
WO2012126390A1 (en) * 2011-03-23 2012-09-27 Hong Kong Baptist University Autophagy inducing compound and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101342259A (en) * 2008-06-18 2009-01-14 沈阳药科大学 Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof
CN101862304A (en) * 2010-07-23 2010-10-20 贵州百花医药股份有限公司 Uncaria sustained-release tablet and preparation method thereof
WO2012126390A1 (en) * 2011-03-23 2012-09-27 Hong Kong Baptist University Autophagy inducing compound and use thereof
CN102311435A (en) * 2011-07-05 2012-01-11 南京泽朗农业发展有限公司 Preparation method for high purity rhynchophylline

Similar Documents

Publication Publication Date Title
Reynolds et al. Cardiogenic shock: current concepts and improving outcomes
Wanner et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial
CN102824545B (en) Blood sugar-reduction traditional Chinese medicine composition
CN103356956B (en) Traditional Chinese medicine composition for treating autoimmune liver disease and preparation method thereof
AU2004290484B8 (en) Treatment of Aspirin Resistance with Radix Salviae Miltiorrhizae, its extract and composition
CN101890125B (en) Medicament for treating hyperthyroidism and preparation method thereof
Pellicori et al. Fluid management in patients with chronic heart failure
CN103623248A (en) Traditional Chinese medicinal composition for reducing blood pressure
CN105727015A (en) Composition for regulating blood lipid and blood pressure and preparation method thereof
CN103937655B (en) White spirit with anti-fatigue function and production method thereof
CN104000197A (en) Health care product or medicine composition capable of relieving fatigue and preparation method and purpose thereof
CN104095945A (en) Traditional Chinese medicine composition for treating chronic cardiac failure and oral preparation thereof
CN101849957A (en) Application of Dendrobium officinale polysaccharide in preparation of medicine for preventing and treating hypertension and apoplexy
CN106924712A (en) A kind of compound sustained-released tablet of new anti-hypertension and production technology
CN101417132B (en) Use of medicine combination comprising carvedilol and angiotensin II recipient antagonist in preparing medicine for treating kidney disease
CN101347495B (en) Preparation of Glabridin dispersible tablets and use of the tablets in reducing blood sugar as medicament active composition
CN102008710B (en) Lisinopril-containing compound preparation for treating hypertension
CN102579886A (en) Chinese medicine for treating nephrotic syndrome
Van Uum Liquorice and hypertension
CN104971102B (en) The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy
CN104758353B (en) A kind of pharmaceutical composition and its preparation method and application for treating angiocardiopathy
CN103920025A (en) Pharmaceutical composition for treating hypertension and application thereof
CN102488815A (en) Buccal tablet for reducing blood sugar
Oguzturk et al. Complete atrioventricular block caused by mad honey intoxication
CN101708306A (en) Chinese medicinal composition for treating gastropathy and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131127